Breast Cancer Research | Home page

Breast Cancer Research | Home page



Breast Cancer Research

Featured review: Cancer stem cell metabolism

Even though cancer is now viewed as a stem cell disease, there is still no consensus on the metabolic characteristics of these cells. This review by Maria Peiris-Pagès et al. summarizes the latest findings and discoveries on cancer stem cell metabolism.

Articles

• Recent
• Most accessed

Recent articles RSS

1. RESEARCH ARTICLE

   EZH2 protein expression in normal breast epithelium and risk of breast cancer: results from the Nurses’ Health Studies

   Francisco Beca, Kevin Kensler, Benjamin Glass, Stuart J. Schnitt, Rulla M. Tamimi and Andrew H. Beck

   Published on: 2 March 2017
2. RESEARCH ARTICLE

   Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty

   Jithendra Kini Bailur, Graham Pawelec, Sigrid Hatse, Barbara Brouwers, Ann Smeets, Patrick Neven, Annouschka Laenen, Hans Wildiers and Christopher Shipp

   Published on: 28 February 2017
3. RESEARCH ARTICLE

   Modification of the association between recreational physical activity and survival after breast cancer by promoter methylation in breast cancer-related genes

   Lauren E. McCullough, Jia Chen, Yoon Hee Cho, Nikhil K. Khankari, Patrick T. Bradshaw, Alexandra J. White, Susan L. Teitelbaum, Mary Beth Terry, Alfred I. Neugut, Hanina Hibshoosh, Regina M. Santella and Marilie D. Gammon

   Published on: 21 February 2017
4. RESEARCH ARTICLE

   Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy

   Antonino Musolino, Mario Campone, Patrick Neven, Neelima Denduluri, Carlos H. Barrios, Javier Cortes, Kimberly Blackwell, Hatem Soliman, Zsuzsanna Kahan, Hervé Bonnefoi, Matthew Squires, Yong Zhang, Stephanie Deudon, Michael M. Shi and Fabrice André

   Published on: 10 February 2017
5. RESEARCH ARTICLE

   Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

   Giampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, Young-Hyuck Im, Tadeusz Pienkowski, Mei-Ching Liu, Ling-Ming Tseng, Mitch Dowsett, Lila Zabaglo, Sarah Kirk, Tania Szado, Jennifer Eng-Wong, Lukas C. Amler, Pinuccia Valagussa and Luca Gianni

   Published on: 9 February 2017

View all articles

Meet the Editor-in-Chief

Dr. Lewis A. Chodosh is a physician-scientist who received a BS in Molecular Biophysics and Biochemistry from Yale University, and MD from Harvard Medical School, and a PhD. in Biochemistry from M.I.T. in the laboratory of Dr. Phillip Sharp. He performed his clinical training in Internal Medicine and Endocrinology at the Massachusetts General Hospital, after which he was a postdoctoral research fellow with Dr. Philip Leder at Harvard Medical School. Dr. Chodosh joined the faculty of the University of Pennsylvania in 1994, where he is currently a Professor in the Departments of Cancer Biology, Cell & Developmental Biology, and Medicine. He serves as Chairman of the Department of Cancer Biology, Associate Director for Basic Science of the Abramson Cancer Center, and Director of Cancer Genetics for the Abramson Family Cancer Research Institute at the University of Pennsylvania. Additionally, he is on the scientific advisory board for the Harvard Nurses' Health Studies I and II. 

Dr. Chodosh's research focuses on genetic, genomic and molecular approaches to understanding breast cancer susceptibility and pathogenesis.